Abstract
Context:
The use of aspirin in chronic kidney disease (CKD) patients has been shown to reduce myocardial infarction but may increase major bleeding. However, its effects in kidney transplant recipients are unclear.
Evidence Acquisitions:
A literature search was performed using MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews from inception through September 2016. We included studies that reported odd ratios, relative risks or hazard ratios comparing outcomes of aspirin use in kidney transplant recipients. Pooled risk ratios (RR) and 95% confidence interval (CI) were assessed using a random-effect, generic inverse variance method.
Results:
We included 9 studies; enrolling 19759 kidney transplant recipients that compared aspirin with no treatment. Compared to no treatment, aspirin reduced the risk of allograft failure (4 studies; RR: 0.57, 95% CI: 0.33 to 0.99), allograft thrombosis (2 studies; RR: 0.11, 95% CI: 0.02 to 0.53), and major adverse cardiac events (MACEs) or mortality (2 studies; RR: 0.72, 95% CI: 0.59 to 0.88), but not allograft rejection (3 studies; RR: 0.86, 95% CI: 0.45 to 1.65) or delayed graft function (DGF) (2 studies; RR: 1.00, 95% CI: 0.58 to 1.72) in kidney transplant recipients. The data on risk of major or minor bleeding were limited.
Conclusions:
Our meta-analysis demonstrates that administration of aspirin in kidney transplant recipients is associated with reduced risks of allograft failure, allograft thrombosis, and MACEs or mortality, but not allograft rejection or DGF. Future studies are needed to assess the risk of bleeding, and ultimately weigh the overall risks and benefits of aspirin use in specific kidney transplant patient populations.
Keywords: Aspirin, Kidney transplantation, Delayed graft function, Allograft failure, Transplantation
Implication for health policy/practice/research/medical education:
The effects of aspirin use on allograft outcomes are unclear. In this meta-analysis including 9 studies with 19 759 kidney transplant recipients, we demonstrate significant associations between the use of aspirin and a 0.57-fold reduced risk of allograft failure, 0.11-fold reduced risk of allograft thrombosis and 0.72-fold reduced risk of major adverse cardiac events (MACEs) or mortality.
1. Background
The administration of aspirin in patients with chronic kidney disease (CKD) has been shown to provide similar potential benefit for cardiovascular risk reduction in CKD and non-CKD patients (1). Despite the fact that the use of aspirin and other antiplatelet agents in CKD patients may reduce myocardial infarction, data from randomized controlled trials (RCTs) showed that antiplatelet agents also significantly increased major bleeding in CKD patients (1-3). Thus, the use of aspirin in CKD patients may outweigh harms among patients with low annual risks of cardiovascular events (2).
In kidney transplant recipients, notwithstanding significant improvements in short-term kidney allograft survival (4), long-term graft and patients survivals are still an ongoing concern (5,6). In addition, cardiovascular disease remains the most common cause of death after kidney transplantation worldwide (7,8). Previous studies of kidney transplant recipients have shown no significant benefits of antiplatelet agents, including dipyridamole and picotamide, in the reduction of allograft rejection or improvement of allograft survival (2,9-11).
The effects of aspirin administration on allograft outcomes including allograft thrombosis, delayed graft function (DGF), acute/chronic allograft rejection and major adverse cardiac events (MACEs) or mortality, however, are not clearly demarcated. A few studies have demonstrated these beneficial effects of aspirin in kidney transplant recipients (12-15). Conversely, several studies have shown no significant effects (16-20) in kidney transplant population. Thus, we conducted a meta-analysis to assess the effects of aspirin on these kidney allograft outcomes.
2. Evidence Acquisition
2.1. Search strategy
W.C. and C.T. (two investigators) independently searched published articles and conference abstracts listed in EMBASE, MEDLINE and the Cochrane database from inception through September 2016 using the following words: “aspirin” AND “transplantation” AND “kidney” or “renal” (Item S1 in online supplementary data). A manual search for additional relevant studies using references from retrieved articles was also performed. Differing decisions were resolved by mutual consensus.
2.2. Inclusion criteria and outcomes
The inclusion criteria were 1) RCTs or observational studies published as original studies or conference abstracts that assessed the effects of aspirin in kidney transplant populations, 2) studies that presented data to calculate relative risks, hazard ratios, or standardized incidence ratios with 95% confidence intervals (CI), and 3) a reference group composed of patients who were not on treatment with aspirin as control group.
Our outcomes of interest in this study included allograft failure, allograft thrombosis, allograft rejection, DGF and MACEs or mortality. The quality of each study was evaluated by using the Jadad quality-assessment scale (21) for RCTs and the Newcastle-Ottawa quality assessment scale (22) for observational studies.
2.3. Data extraction
A standardized data collection form was utilized to extract the following information: study design, last name of first author, title of article, year of study, country of origin, year of publication, sample size, definition of aspirin use and control groups, and point of outcome assessment.
2.4. Statistical analysis
Review manager software (version 5.3) from the Cochrane collaboration was utilized for data analysis. Point estimates and standard errors were obtained from individual studies and were consolidated by the generic inverse variance method of DerSimonian and Laird (23). A random-effect model was employed rather than a fixed-effect model, given the high likelihood of between-study variances. Statistical heterogeneity was appraised using Cochran’s Q test. This statistic was complemented with the I2 statistic, which quantifies the proportion of the total variation across studies that is due to heterogeneity rather than chance. An I2 of 0%–25% renders insignificant heterogeneity, 26%–50% low heterogeneity, 51%–75% moderate heterogeneity and >75% high heterogeneity (24). The possibility of publication bias was evaluated by funnel plots of the logarithm of odds ratios vs. their standard errors (25).
3. Results
The search strategy yielded 2225 potentially relevant articles: 2117 were excluded based on the title and abstract which apparently showed that they did not fulfill inclusion criteria regarding study design, article type, population, or outcome of interest (Item S2). The remaining 108 articles underwent full-length review, with 99 excluded because they were not observational studies or RCTs (n = 12) or did not report outcomes of interest (n = 87). Nine cohort studies with 19 759 kidney transplant recipients that compared aspirin with no treatment were included in the meta-analysis. Table 1 contains detailed characteristics and quality assessment of all included studies.
Table 1. Main characteristics of the observational studies included in this meta-analysis .
| Abendroth et al (16) | Taha et al (17) | Robertson et al (12) | |
| Country | Germany | UK | UK |
| Study design | Cohort study | Cohort study | Cohort study |
| Year | 1997 | 2000 | 2000 |
| Total number | 176 | 226 | 955 |
| Study sample | Kidney transplant patients | Cadaveric kidney transplant patients | Cadaveric and living related kidney transplant patients receiving cyclosporine-based tripple immunosuppression |
| Exposure definition | 0.5 g aspirin prior to declamping | Daily aspirin 150 mg for the first 3 postoperative months | Aspirin 75-150 mg once daily for 1 month post-transplant or long-term for high-risk patients |
| Adjusted OR or RR for outcome |
Rejection 1.65 (0.91-3.00) 36-month graft failure 0.71 (0.31-1.61) 36-month mortality 0.48 (0.14-1.64) |
Primary allograft thrombosis 0 2-year graft failure 0.99 (0.50-1.96) Chronic rejection 0.54 (0.28-1.04) |
Renal vein thrombosis 0.21 (0.09-0.51) |
| Confounder adjusted | Matched for age, gender, cold ischemia time, HLA-match, immunosuppressive regimen, and panel-reactive antibodies | None | None |
| Quality assessment (Newcastle-Ottawa scale) |
Selection:3 Comparability: 2 Outcome: 2 |
Selection:3 Comparability: 0 Outcome: 2 |
Selection:2 Comparability: 0 Outcome: 2 |
| Murphy et al (18) | Grotz et al (13) | Oien et al (19) | |
| Country | UK | Germany | Northern Europe and Canada |
| Study design | Cohort study | Cohort study | Cohort study |
| Year | 2001 | 2004 | 2006 |
| Total number | 226 | 830 | 1052 |
| Study sample | Cadaveric kidney transplant patients | Kidney transplant patients | Kidney transplant patients |
| Exposure definition | Aspirin 150 mg daily for the first 3 months after transplant | Aspirin 100 mg daily | Aspirin use at baseline |
| Adjusted OR or RR for outcome |
Delayed graft function 1.18 (0.67-2.07) Acute rejection 0.71 (0.41-1.24) |
Graft failure; defined as death of the patient or the need to return to chronic dialysis therapy 0.44 (0.32-0.61) |
Non-fatal MI or cardiac death 1.36 (0.81-2.28) |
| Confounder adjusted | None | Statin, number of antihypertensive medications, gender, donor type, acute allograft rejection, age, number of transplantation, period of transplantation, HLA mismatch, warm ischemia time, cold ischemia time and renal diseases | None |
| Quality assessment (Newcastle-Ottawa scale) |
Selection:2 Comparability: 0 Outcome: 2 |
Selection:4 Comparability: 2 Outcome: 3 |
Selection:4 Comparability: 0 Outcome: 3 |
| Stechman et al (14) | Pilmore (15) | Esfandiar et al (20) | |
| Country | UK | Multi-center | Iran |
| Study design | Cohort study | Cohort study | Cohort study |
| Year | 2007 | 2011 | 2012 |
| Total number | 797 | 15 410 | 87 |
| Study sample | Cadaveric and living related kidney transplant patients | Kidney transplant patients | Pediatric kidney transplant patients |
| Exposure definition | Aspirin 75 mg daily for 28 days following transplant | Anti-platelet use within 4 months and 12 months post-transplant | Heparin 50 units/kg every 8 hours for 7 days and aspirin 5 mg/kg three times a week from day 3 of transplant for 3 months |
| Adjusted OR or RR for outcome | Renal vein thrombosis 0.04 (0.01-0.30) |
Major adverse cardiac events At 12 months 0.95 (0.67-1.36) At 5 years 0.73 (0.60-0.89) |
Thrombosis 0 Graft failure 0.14 (0.02-1.12) Acute tubular necrosis 1.44 (0.50-4.17) |
| Confounder adjusted | None | Age, race, BMI, cause of renal failure, time on dialysis, panel reactive antibodies, history of cardiovascular disease risk factors | Matched for age and sex |
| Quality assessment (Newcastle-Ottawa scale) |
Selection:2 Comparability: 0 Outcome: 2 |
Selection:4 Comparability: 2 Outcome: 3 |
Selection:3 Comparability: 1 Outcome: 2 |
3.1. Effects of aspirin on kidney allograft outcomes
The pooled risk ratio (RR) of allograft thrombosis in recipients (2 studies) who received aspirin was 0.11 (95% CI: 0.02-0.53, I2 = 66%) as shown in Figure 1. However, compared to no treatment, aspirin did not significantly reduce the risk of DGF with pooled RR (2 studies) of 1.00 (95% CI: 0.58-1.72, I2 = 0%) (Figure S1) or acute/chronic allograft rejection with pooled RR (3 studies) of 0.86 (RR: 0.86, 95% CI: 0.45-1.65, I2 = 71%) (Figure S2). Nevertheless, aspirin significantly decreased the risk of allograft failure (4 studies; RR: 0.57, 95% CI: 0.33 to 0.99, I2 = 55%) as shown in Figure 2.
Figure 1.
Forest plot of all included studies comparing risk of allograft thrombosis in kidney transplant recipients who received aspirin vs control; square data markers, RRs; horizontal lines, 95% CIs, with marker size reflecting statistical weight of study using random-effects meta-analysis. Diamond data markers, overall RRs and 95% CIs for outcomes of interest. IV, inverse variance; SE, standard error.
Figure 2.
Forest plot of all included studies comparing risk of allograft failure in kidney transplant recipients who received aspirin vs control; square data markers, RRs; horizontal lines, 95% CIs, with marker size reflecting statistical weight of study using random-effects meta-analysis. Diamond data markers, overall RRs and 95% CIs for outcomes of interest. IV, inverse variance; SE, standard error
3.2. Effects of aspirin on major adverse cardiac events or mortality
The pooled RR of MACEs or mortality in recipients (3 studies) who received aspirin was 0.86 (95% CI: 0.52-1.43, I2 = 63%) (Figure S3). When meta-analysis was limited only to the studies with adjusted analysis to minimize the effects of confounders, the pooled RR of MACEs or mortality was 0.72 (95% CI: 0.59-0.88, I2 = 0%) (Figure S4).
3.3. Evaluation for publication bias
Funnel plots to evaluate publication bias regarding the risks of allograft failure and MACEs or mortality in recipients using aspirin are shown in Figure S5-6. Overall, the publication bias was insignificant. However, due to the limited number of studies, the power of the test was too low to distinguish chance from real asymmetry (26).
4. Discussion
In this meta-analysis of 19 759 kidney transplant patients, we demonstrated significant associations between the use of aspirin and a 0.57-fold reduced risk of allograft failure, 0.11-fold reduced risk of allograft thrombosis and 0.72-fold reduced risk of MACEs or mortality. However, the use of aspirin did not significantly decrease DGF or allograft rejection. In addition, the data on risk of major or minor bleeding in recipients with aspirin use were limited.
Atherosclerosis is an important and common component in the pathogenesis of chronic allograft failure (27,28). Chronic transplant vasculopathy and atherosclerosis are both recognized as special forms of inflammatory reactions within the vessel wall (27-29). Platelets have long been identified as major determinants, especially in the process of plaque rupture and vessel occlusion or stenosis (13,29). In addition, the degree of transplant vasculopathy is also correlated with the activation status of platelets (30,31). Studies have identified soluble CD40L as an important link between platelet activation and inflammation (32-34), and the blockade of the CD40 and CD40L system has been shown to suppress allograft transplant arteriopathy (31). Additionally, Grotz et al (13) demonstrated that the positive impact of aspirin treatment on long-term kidney transplantation outcome was associated with the duration of aspirin treatment (13). Therefore, our meta-analysis confirmed associations between the use of aspirin and reduced risks of allograft thrombosis and allograft failure in kidney transplant recipients.
Aspirin has been proved to be effective in primary and secondary prevention of cardiovascular disease complications (35,36). Since kidney transplant recipients are considered as moderate to high risk for cardiovascular diseases (37), not surprisingly, our studies also showed an association between reduced risk of MACEs or mortality. Despite the benefits of aspirin, studies have demonstrated that antiplatelet agents could be harmful with significantly increased risk of major bleeding in CKD patients (1-3). Unfortunately, the data on risks of major or minor bleeding associated with aspirin use in kidney transplant recipients were unclear. Although a study of 15 181 percutaneous core biopsies (including a kidney biopsies) showed that the incidence of bleeding in patients receiving aspirin within 10 days before biopsy and those not taking aspirin was not significantly different (38), the data on other types of bleeding such as gastrointestinal (GI) bleeding are limited. In the general population, a recent meta-analysis demonstrated that GI bleeding with low-dose aspirin had an incidence of 0.48-3.64 cases per 1000 person-years and an overall 1.4-fold increased risk (39). In addition, compared with aspirin alone, an increased bleeding risk was observed with use of aspirin combined with non-steroidal anti-inflammatory drugs, clopidogrel and selective serotonin reuptake inhibitors (39).
There are several limitations of our meta-analysis. First, this current study is a meta-analysis of observational studies. Thus, a causal relationship needs to be cautiously interpreted. Second, the majority of the included studies did not have available kidney allograft biopsy information, and consequently, the cause of allograft dysfunction or allograft failure was not known. However, from all available data, it is most likely that the association between aspirin use and reduced risk of allograft failure is through lowered risk of transplant vasculopathy and atherosclerosis (13,31-34). Finally, studies have shown reduced patient survival in kidney transplant recipients with elevated cardiac troponin T (cTnT) (40,41). The data on the risk and benefits of aspirin especially in these high-risk transplant populations, however, were lacking in the included studies in our meta-analysis.
5. Conclusions
In summary, this meta-analysis shows reduced risks of allograft failure, allograft thrombosis and MACEs or mortality, but not allograft rejection or DGF among renal transplant recipients treated with aspirin. Ultimately to weigh the overall risks and benefits of aspirin use in specific kidney transplant patient populations, future studies assessing the major or minor bleeding risks in aspirin treated kidney transplant recipients are required.
Conflicts of interest
The authors declare that they have no conflicting interest.
Authors’ contributions
All authors had access to the data and a role in writing the manuscript. All authors read and signed the final paper.
Funding/Support
None.
Supplementary Materials
Supplementary Data contains Item S1, Item S2, and Figures S1-S6.
Please cite this paper as: Cheungpasitporn W, Thongprayoon C, Mitema DG, Michael A. Mao MA, Sakhuja A, et al. The effect of aspirin on kidney allograft outcome; a short review to current studies. J Nephropathol. 2017;6(3):110-117. DOI: 10.15171/jnp.2017.19.
References
- 1.Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG. et al. Cardiovascular disease in chronic kidney disease A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2011;80(6):572–86. doi: 10.1038/ki.2011.223. [DOI] [PubMed] [Google Scholar]
- 2.Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F. et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013;(2):Cd008834. doi: 10.1002/14651858.CD008834.pub2. [DOI] [PubMed] [Google Scholar]
- 3.Floege J, Schlieper G. Chronic kidney disease: How effective and safe are antiplatelet agents in CKD? Nat Rev Nephrol. 2013;9(6):314–6. doi: 10.1038/nrneph.2013.83. [DOI] [PubMed] [Google Scholar]
- 4.Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605–12. doi: 10.1056/nejm200003023420901. [DOI] [PubMed] [Google Scholar]
- 5.Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4(8):1289–95. doi: 10.1111/j.1600-6143.2004.00515.x. [DOI] [PubMed] [Google Scholar]
- 6.Cheungpasitporn W, Thongprayoon C, Mao MA, Kittanamongkolchai W, Sathick IJ, Erickson SB. The effect of renin-angiotensin system inhibitors on kidney allograft survival: a systematic review and meta-analysis. N Am J Med Sci. 2016;8(7):291–6. doi: 10.4103/1947-2714.187141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hart A, Weir MR, Kasiske BL. Cardiovascular risk assessment in kidney transplantation. Kidney Int. 2015;87(3):527–34. doi: 10.1038/ki.2014.335. [DOI] [PubMed] [Google Scholar]
- 8.Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int. 2015;28(1):10–21. doi: 10.1111/tri.12413. [DOI] [PubMed] [Google Scholar]
- 9.Schulze R, Langkopf B, Sziegoleit W. [The effect of dipyridamole on the results of allogenic kidney transplantation] Z Urol Nephrol. 1990;83(5):255–9. [PubMed] [Google Scholar]
- 10.Anderson M, Dewar P, Fleming LB, Hacking PM, Morley AR, Murray S. et al. A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clin Nephrol. 1974;2(3):93–9. [PubMed] [Google Scholar]
- 11.Quarto Di Palo F, Elli A, Rivolta R, Parenti M, Palazzi P, Zanussi C. Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplant Proc. 1991;23(1 Pt 2):969–71. [PubMed] [Google Scholar]
- 12.Robertson AJ, Nargund V, Gray DW, Morris PJ. Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients. Nephrol Dial Transplant. 2000;15(11):1865–8. doi: 10.1093/ndt/15.11.1865. [DOI] [PubMed] [Google Scholar]
- 13.Grotz W, Siebig S, Olschewski M, Strey CW, Peter K. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation. 2004;77(12):1848–53. doi: 10.1097/01.tp.0000129407.31494.45. [DOI] [PubMed] [Google Scholar]
- 14.Stechman MJ, Charlwood N, Gray DW, Handa A. Administration of 75 mg of aspirin daily for 28 days is sufficient prophylaxis against renal transplant vein thrombosis. Phlebology. 2007;22(2):83–5. doi: 10.1258/026835507780346187. [DOI] [PubMed] [Google Scholar]
- 15.Pilmore HL, Skeans MA, Snyder JJ, Israni AK, Kasiske BL. Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. Transplantation. 2011;91(5):542–51. doi: 10.1097/TP.0b013e31820437bd. [DOI] [PubMed] [Google Scholar]
- 16.Abendroth D, Schelzig H, Mickley V, Storck M. Long-term effect of cyclooxygenase inhibition with acetylsalicylic acid in cadaveric renal transplants. Transplant Proc. 1997;29(7):3004–5. doi: 10.1016/S0041-1345(97)00761-6. [DOI] [PubMed] [Google Scholar]
- 17.Taha R, White SA, Horsburgh T, Nicholson ML. Antithrombotic effects of aspirin after renal transplantation. Transplant Proc. 2000;32(3):550. doi: 10.1016/S0041-1345(00)00885-X. [DOI] [PubMed] [Google Scholar]
- 18.Murphy GJ, Taha R, Windmill DC, Metcalfe M, Nicholson ML. Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. Br J Surg. 2001;88(2):261–6. doi: 10.1046/j.1365-2168.2001.01671.x. [DOI] [PubMed] [Google Scholar]
- 19.Oien CM, Reisaeter AV, Os I, Jardine A, Fellstrom B, Holdaas H. Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clin Transplant. 2006;20(3):374–82. doi: 10.1111/j.1399-0012.2006.00496.x. [DOI] [PubMed] [Google Scholar]
- 20.Esfandiar N, Otukesh H, Sharifian M, Hoseini R. Protective effect of heparin and aspirin against vascular thrombosis in pediatric kidney transplants. Iran J Kidney Dis. 2012;6(2):141–5. [PubMed] [Google Scholar]
- 21.Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
- 22.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi: 10.1007/s10654-010-9491-z. [DOI] [PubMed] [Google Scholar]
- 23.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. doi: 10.1016/j.cct.2015.09.002. [DOI] [PubMed] [Google Scholar]
- 24.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867–72. doi: 10.1016/0140-6736(91)90201-Y. [DOI] [PubMed] [Google Scholar]
- 26. Higgins J. Greene S. Cochrane handbook for systematic reviews of interventions. USA: The Cochrane Collaboration; 2011. http://training.cochrane.org/handbook.
- 27.Libby P, Pober JS. Chronic rejection. Immunity. 2001;14(4):387–97. doi: 10.1016/S1074-7613(01)00119-4. [DOI] [PubMed] [Google Scholar]
- 28.Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43. doi: 10.1161/hc0902.104353. [DOI] [PubMed] [Google Scholar]
- 29.Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115–26. doi: 10.1056/nejm199901143400207. [DOI] [PubMed] [Google Scholar]
- 30.Fateh-Moghadam S, Bocksch W, Ruf A, Dickfeld T, Schartl M, Pogatsa-Murray G. et al. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy. Circulation. 2000;102(8):890–7. doi: 10.1161/01.CIR.102.8.890. [DOI] [PubMed] [Google Scholar]
- 31.Wang CY, Mazer SP, Minamoto K, Takuma S, Homma S, Yellin M. et al. Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions. Circulation. 2002;105(13):1609–14. doi: 10.1161/01.CIR.0000013022.11250.30. [DOI] [PubMed] [Google Scholar]
- 32.May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation. 2002;106(16):2111–7. doi: 10.1161/01.CIR.0000033597.45947.0F. [DOI] [PubMed] [Google Scholar]
- 33.Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89(12):1092–103. doi: 10.1161/hh2401.101272. [DOI] [PubMed] [Google Scholar]
- 34.Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM. et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348(12):1104–11. doi: 10.1056/NEJMoa022600. [DOI] [PubMed] [Google Scholar]
- 35.Lauer MS. Clinical practice Aspirin for primary prevention of coronary events. N Engl J Med. 2002;346(19):1468–74. doi: 10.1056/NEJMcp012672. [DOI] [PubMed] [Google Scholar]
- 36.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj. 2002;324(7329):71–86. doi: 10.1136/bmj.324.7329.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Cosio FG, Hickson LJ, Griffin MD, Stegall MD, Kudva Y. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant. 2008;8(3):593–9. doi: 10.1111/j.1600-6143.2007.02101.x. [DOI] [PubMed] [Google Scholar]
- 38.Atwell TD, Smith RL, Hesley GK, Callstrom MR, Schleck CD, Harmsen WS. et al. Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. AJR Am J Roentgenol. 2010;194(3):784–9. doi: 10.2214/ajr.08.2122. [DOI] [PubMed] [Google Scholar]
- 39.Garcia Rodriguez LA, Martin-Perez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS One. 2016;11(8):e0160046. doi: 10.1371/journal.pone.0160046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Hickson LJ, El-Zoghby ZM, Lorenz EC, Stegall MD, Jaffe AS, Cosio FG. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. Am J Transplant. 2009;9(6):1354–61. doi: 10.1111/j.1600-6143.2009.02636.x. [DOI] [PubMed] [Google Scholar]
- 41.Keddis MT, El-Zoghby ZM, El Ters M, Rodrigo E, Pellikka PA, Jaffe AS. et al. Cardiac troponin T before and after kidney transplantation: determinants and implications for posttransplant survival. Am J Transplant. 2013;13(2):406–14. doi: 10.1111/j.1600-6143.2012.04317.x. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Data contains Item S1, Item S2, and Figures S1-S6.